This new global meeting will bring together a carefully curated group of international leaders across oncology, haematology, diagnostics, pharmacy, and healthcare innovation for two days of high-level dialogue, collaboration, and clinically relevant education focused on improving patient outcomes worldwide
The Network for Collaborative Oncology Development & Advancement (NCODA), a globally recognised non-profit organisation dedicated to improving quality, safety, and access in oncology care, today announced the launch of its inaugural Global Oncology & Haematology Congress, taking place March 11-12, 2026 at The Shelbourne Hotel, Dublin.
This new global meeting will bring together a carefully curated group of international leaders across oncology, haematology, diagnostics, pharmacy, and healthcare innovation for two days of high-level dialogue, collaboration, and clinically relevant education focused on improving patient outcomes worldwide.
Designed to foster meaningful exchange and real-world impact, the Congress will explore critical issues shaping the future of cancer care, including treatment sequencing, therapy management, patient adherence, precision oncology, digital health, and the expanding role of medically integrated oncology care models.
“Cancer care is evolving rapidly, and collaboration across disciplines and borders has never been more important,” said Michael Reff, RPh, MBA, Founder and Executive Director of NCODA. “The Global Oncology and Haematology Congress is intentionally designed to bring together leaders who are actively reshaping how cancer care is delivered. By convening experts from pharmacy, medicine, diagnostics, and health systems, we aim to share practical solutions that improve care quality, access, and patient outcomes globally.”
The Congress programme will feature internationally recognised faculty from Europe, North America, and beyond, offering advanced, clinically relevant education and actionable strategies that oncology teams can apply immediately in practice. Sessions will address topics such as sustainable oncology amid global drug shortages, AI-driven cancer care, cardio-oncology, precision medicine, workforce protection, and community-centred models of care.
There will be 16 sessions over two days, with a wide variety of topics being tackled, including:
- AI-Driven Cancer Care: The Technology Transforming Oncology Worldwide
- Precision Oncology in Motion: Genomics, Biomarkers, and the New Era of Personalised Treatment
- Sustainable Oncology: Innovative Solutions to Global Drug Shortages
The full agenda can be found here.
Participants will also gain exclusive insight into NCODA’s standards, tools, and educational initiatives that support oncology practices in delivering high-quality, patient-centred care, as well as opportunities to connect with physicians, pharmacists, nurses, technicians, trainees, and industry partners from around the world.
Speaking of the upcoming inaugural congress, Dave Shanahan, NCODA Global Council Steering Committee Member and CEO of Athena Pharmaceuticals, said, “It’s so welcome that an international charity like NCODA has chosen Dublin for their global meeting in 2026, supporting knowledge sharing in the clinical community who deliver cancer care. It recognises Irish advances in improving clinical outcomes for people diagnosed with cancer, as well as addressing prevention and treatment-based opportunities to improve outcomes further. Irish academic, clinical and patient groups want to build on the great work done to date to increase prevention and advance standards in cancer care further.”
While Eoin Tabb, NCODA Global Council Steering Committee Member and said on behalf of the Irish Pharmacy Haematology Oncology Society (IPHOS), “The NCODA Global Congress is essential for connecting global oncology leaders to drive forward best practices and patient-centred innovation in our field. I’m participating in this event and would encourage everyone with an interest to attend too.”
Marko Skelin, NCODA’s International Executive Council Chair and Global Congress Steering Committee Member and Deputy Director at General Hospital Sibenik, said, “This Global Congress unites multidisciplinary experts dedicated to improving outcomes and quality of life for patients with cancer. The robust agenda equips attendees with practical, evidence-based approaches that enhance patient experience and outcomes in everyday practice.”
The Global Oncology & Haematology Congress is intentionally structured to encourage thoughtful discussion, showcase real-world innovation, and strengthen partnerships across disciplines and geographies. NCODA believes the diverse perspectives and leadership of attendees will be central to shaping the meeting’s conversations and outcomes.
Early registration is encouraged, as attendance is limited to maintain a highly engaged and collaborative environment. The early bird booking deadline ends on February 16, 2026.
Additional details about the Congress agenda and experience are available on the event page.
<
Leave a Reply